19 June 2013
Keywords: nice, rejects, gsk, tyverb, too, expensive, second
Article | 20 October 2008
Tyverb (lapatinib) has been deemed too expensive for use by the UK's National Health Service, despite an offer from drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 October 2008
1 December 2008
8 September 2008
© 2013 thepharmaletter.com